<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02458183</url>
  </required_header>
  <id_info>
    <org_study_id>BR-DTPP-CT-301</org_study_id>
    <nct_id>NCT02458183</nct_id>
  </id_info>
  <brief_title>Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS</brief_title>
  <acronym>Venus</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV
      combination vaccine compared with those of separate DTaP and IPV vaccines administered to
      healthy infants at 2, 4, and 6 months of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multinational, multicenter, randomized, comparative, open-label, phase 3 study

      Primary Objective: To assess the vaccine response rates after the three-dose primary
      vaccination Secondary Objectives: To measure the antibody titer after the three-dose primary
      vaccination and to assess the safety of the investigational products
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine response rate</measure>
    <time_frame>4 weeks after the three-dose primary vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT)</measure>
    <time_frame>4 weeks after the three-dose primary vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">476</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>DTaP-IPV combination vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTaP vaccine and IPV vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.
Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV combination vaccine</intervention_name>
    <description>0.5-mL IM</description>
    <arm_group_label>DTaP-IPV combination vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP vaccine and IPV vaccine</intervention_name>
    <description>0.5-mL IM</description>
    <arm_group_label>DTaP vaccine and IPV vaccine</arm_group_label>
    <other_name>Boryung DTaP Vaccine Inj. (Prefilled syringe)</other_name>
    <other_name>IPVAX INJ. PREFILLED SYRINGE INJ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent/guardian (legally authorized representative) has given voluntary written
             consent to the subject's participation after being fully informed of the purpose,
             methods, risks, and benefits of the study.

          -  Male and female infants reaching at least 7 weeks of age on the day of first dose of
             investigational product.

          -  Male and female infants who are identified to be healthy based on physical examination
             and medical history.

        Exclusion Criteria:

          -  Subjects who have acute febrile illness with tympanic temperature of ≥38.0 ℃ on the
             day of vaccination.

          -  Subjects who have moderate or severe acute disease (regardless of fever).

          -  Subjects who have any history of diphtheria, tetanus, pertussis, or poliomyelitis.

          -  Subjects who have major congenital defects.

          -  Subjects who show any evidence of continuous hematologic, hepatic, cardiac, re-nal, or
             respiratory disease.

          -  Subjects who have abnormalities in the immune system, or congenital/acquired immune
             deﬁciency.

          -  Subjects who received immunosuppressive dose of systemic corticosteroids thera-py
             within 30 days before the vaccination.

          -  Subjects who are likely to have adverse side effects on central nervous system
             be-cause of the subjects' family history of genetic diseases in central nervous system
             such as progressive neurological problems or epilepsy.

          -  Subjects who are allergic to the ingredients of the investigational products.

          -  Subjects who have received immunoglobulins or blood products or plan to get those
             medications.

          -  Subjects who have received vaccines other than those allowed in the protocol or plan
             to get those prohibited vaccines during the study period.

          -  Subjects who are currently participating or planning to participate in other clinical
             studies during the study period.

          -  Other ineligible conditions judged at the discretion of principal investigators or
             subinvestigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HJ Jung</last_name>
    <role>Study Director</role>
    <affiliation>Boryung Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KeiMyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwangmyeong Sungae Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Jeonbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheil General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulgi General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Sevrance Christian Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEPCO Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Sevrance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thammasat University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonprathan Hospital</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2015</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

